CliffBio
small molecule

NOCTIVA

DESMOPRESSIN ACETATE

Loss of exclusivityJune 2030latest FDA-listed patent expiry
CompanyAcerus Pharmaceuticals →View the full company profile on CliffBio

Drug detail

Brand nameNOCTIVA
Active ingredientDESMOPRESSIN ACETATE
Strength0.00166MG/SPRAY
Dosage formSPRAY, METERED
RouteNASAL
ModalitySmall molecule
FDA approvalMarch 2017
Marketing statusDISCN

Listed patents

PatentExpiresType
11419914June 2030use U-3431
12090190June 2030product
9539302June 2030product

More from Acerus Pharmaceuticals

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

NOCTIVA patent cliff — loss of exclusivity June 2030 | CliffBio